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It is an inherent part of living to be in constant modiﬁcation, which are due to answers resulting from environmental changes. The
diﬀerent systems make adaptations based on natural selection. With respect to the immune system of mammals, these changes
have a lot to do with the interactions that occur continuously with other living species, especially microorganisms. The immune
system is primarily designed to defend from germs and this response triggers inﬂammatory reactions which must be regulated in
order not to generate damage to healthy tissue. The regulatory processes were added over time to prevent such damage. Through
evolution the species have stored “an immunological experience,” which provides information that is important for developing
eﬀective responses in the future. The human species, which is at a high level of evolutionary immunological accumulation, have
multiple immune defense strategies which, in turn, are highly regulated. Imbalances in these can result in autoimmunity.
“There is nothing permanent except change.”
(Heraclitus)
1.Introduction
L i f eb e g a no ne a r t hm o r et h a n3 . 5b i l l i o ny e a r sa g oa n d
evolution has allowed the development of myriads of species
fromverysimpletohighlycomplexones.Initially,unicellular
microorganisms without a nucleus (prokaryotes) similar
to modern bacteria appeared and after that others with a
nucleus similar to amoebas. These ancestral amoebas devel-
oped in groups and have been called “social amoebas.” These
feed on bacteria in the soil and they aggregate when there
is a serious lack of food to form a migrating group. A
type of amoeba in these groups diﬀerentiated and facili-
tated the process of detoxiﬁcation through immunological
mechanisms and became what is called a sentinel (S-cell)
[1]. The S-cell engulfs bacteria and sequesters toxins. This
may be the origin of the immune system. Subsequently, these
unicellular eukaryotes diﬀerentiated into diverse functions
and developed forms of signaling and adhesion molecules
which allowed them to aggregate. This could have been the
beginning of evolution of multicellular organisms (meta-
zoans) which later migrated from the sea [2]. Around 600
million years ago, terrestrial metazoans began to develop
in conjunction with an important increase in the oxygen
concentration in the atmosphere. The vertebrate animals
with their remarkable diversiﬁcation appeared 500 million
years ago in a relatively short time period termed the
“evolutionary big bang.” Since the beginning of life, the most
important element of evolution has been the increasing
abilityoflivingthingstoaccumulateinformationaboutthese
processes at diﬀerent levels of memory.
Recently Dawkins [3], in his masterpiece, showed us
that the diﬀerent forms of memory were the most relevant
foundation for evolution. Information required for handling
the present so as to survive into the future is necessarily2 Autoimmune Diseases
obtained from the past. In fact, he proposed four levels of
information gathering, which he called the “four memories,”
which would be the foundation of evolution. The “ﬁrst
memory” is DNA, the inherited database each species has,
and which is the result of nonrandom evolution. It is the
record of recurrent ancestral and cumulative details resulting
from interaction with the environment which led to the
primary characteristics of each species. The “second mem-
ory” is the adaptive immune system, which is cumulative
information about dangerous microorganisms with which
the individual interacts and through this interaction acquires
the ability to defend itself from subsequent exposure with
high eﬃciency. This process is present during the life of
the individual. The “third memory” is the fact that we can
think and it resides in the nervous system. By mechanisms
that we do not yet fully understand, our brain records past
experiences and works by a trial-and-error process that can
be seen as yet another analogy to natural selection. In the
human species, this level contains lists of faces, places, music,
social customs, rules and words. The “fourth memory” is
the collective memories inherited nongenetically from past
generations and the culture. It also includes the information
gathered through oral tradition and writing and, most
recently, computer systems and Internet. This latter level of
memory is necessary today for human survival.
Over time, the recorded information of repeated pro-
cesses may be stored at a lower level of memory. Like wings
or lungs that are necessary for survival, each adaptive
change was developed as a secondary information-gathering
system and later moved to the primary level. In fact, the
mechanisms of evolution were also involved in the immune
system development. The innate immunity which provides
the early line of defense against microbes was developed by
the perennial need for protection.
Based on these concepts, we are proposing a way to look
at the autoimmune processes from the point of view of evo-
lution with special attention to immune receptors which are
crucial for sensing damage-causing agents and ﬁne tuning
the immune and inﬂammatory response that results. These
receptors go through constant selection changes caused
by the pressure of evolving pathogens. These pathogens
stimulate the development of eﬀective immune reactivity in
order to maximize the destruction of the pathogens while
avoiding an excessive immune and inﬂammatory response
that could lead to consequences such as autoimmunity or
septic shock [4].
In Figure 1, the evolutionary pathways of animal species
are traced and the way the immune system becomes more
complex in cumulative strategies is outlined.
It is important to note that the majority of species alive
today are not from species that still exist but from previous
ones.Thatis,mandidnotdescendfrommonkeys,butshares
a common ancestor. Through the study of species existing
today, it is possible to describe with some degree of precision
what their ancestors were like and how they evolved. Many
species have disappeared and we only know about them
through their fossils [5].
2. Inﬂuence of the FirstForm of Evolutionary
Memory on the Autoimmune Phenomena
Innate immunity is a system that does not create a new
form of memory and should be included in the ﬁrst memory
of evolution. The innate immunity is natural, nonspeciﬁc,
nonanticipatory, and does not generate an accumulation of
information. This system contains cells that resemble phago-
cytes which have generic receptors that recognize conserved
patterns of pathogens and lectine-like soluble proteins, and
they are essential in arthropods, nematodes, sipunculids,
mollusks, annelids, platyhelminths, echinoderms, cephalo-
chordates, and urochordates. Adaptive immunity, which
has a highly diverse repertoire of lymphocytes, was added
in agnathas (vertebrates without jaws) and gnathostomes
(vertebrates with jaws). In fact, in the most complex species
like mammals, the immune system consists of innate and
adaptiveimmunitieswhichincludeTandBlymphocytesand
the production of cytokines and antibodies.
2.1. The Pattern Recognition Receptors (PRRs). Human
innate immunity shares similar cells, cellular structures, and
molecules with invertebrates. The PRRs are of special inter-
est. These include members of nucleotide oligomerization
domain proteins containing leucine-rich repeats (NLRs),
retinoic acid inducing gene (RIG)-like helicases (RLHs), and
toll-like receptors (TLRs) [6]. TLRs deserve special attention
and are one of the largest and best-studied PRRs. They are
expressed on macrophages, dendritic cells, epithelial cells,
and endothelial cells, where they provide rapid responses
including the induction of proinﬂammatory cytokine secre-
tionthatrecruitsandactivatesadditionalimmuneresponses.
Such receptors were highly conserved during evolution and
wereﬁrstidentiﬁedinDrosophilamelanogaster [7].TheTLRs
are necessary for defense from various microorganisms. For
example, it has been demonstrated that mutant Drosophila,
which carries loss-of-function mutations in the toll receptor,
resulted in high susceptibility to fungi infection. The defec-
tive induction of an antifungal peptide provided the ﬁrst
evidencethatDrosophilaexpressesaspeciﬁcreceptorrespon-
sible for sensing a fungi infection [8]. TLR has a leucine-rich
extracellular domain interrupted by cysteine motifs and an
intracytoplasmic domain similar to the interleukin-1 (IL-1)
receptor all of which contain ITAMs domains that make it
possible to follow the cascade of signaling events through
phosphorylation of tyrosine residues [9]. This similarity
betweentheTRLandtheIL-1receptordomainshasthesame
phylogenetic origin in invertebrates and is highly conserved
among them. Nowadays, this domain has been named TIR
(Toll/1L-R). Unlike other human TLRs that are typically
present on the surface of cells and recognize bacterial danger
signals, a group of TLRs including TLR3, TLR7, and TLR9
localize cell endosomes and recognize viral danger signals
(dsRNA, ssRNA, and hypomethylated dsDNA, resp.). This
group of endosomal TLRs has been particularly implicated
inthepathogenesisofautoimmunediseases.Human-derived
RNAsandDNAsthataretargetsofautoimmuneresponsesin
systemic lupus erythematosus (SLE) and related conditions
have been found to induce activation of these receptors [10].Autoimmune Diseases 3
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Figure 1: Phylogeny of animals and their immune system. Notice the form of accumulative evolution of the immune system from an innate
to an adaptive system.
Altered expression and function of these receptors have been
linked to clinical manifestations of lupus-like autoimmunity
inanimalmodels[11,12].Inthecaseofrheumatoidarthritis
(RA), it has been postulated that after the activation of TLR
by exogenous stimuli, these receptors recognize endogenous
proteins. Potential endogenous TLR ligands are head shock
protein (HSP)-60, HSP-70, gp96, high mobility group box
1 protein (HMGB-1), serum amyloid A, and low molecular
weight hyaluronic acid. Therefore, they are capable of
inducing a self-perpetuating inﬂammatory process which
plays an important role in the pathogenesis of RA [13]. This
is a form of autoimmunity related to innate immunity and
it occurs when regulatory systems are scarce and ancestral
mechanisms such as RNA interference (RNAi) are involved
[14]. In the case of primitive animals that possessed only
an innate defense system, such animals might have suﬀered
occasional disregulation which resulted in reactions against
their own bodies and thus, parallel mechanisms to prevent
self-injury had to be developed [15].
2.2. Cytokines. Proinﬂammatory cytokines and their recep-
tors are present in early representatives of metazoans, such as
cnidarians, and seem to be conserved in the entire animal
kingdom. They are a family of secreted and regulatory
molecules with a hormone-like activity and molecular
mass ranging from 10 to 50kDa. Cytokines are produced
transiently and locally. Their mechanism of action is mainly
paracrine or autocrine with the ability to induce a potent
response in very small amounts. Cytokines interact with
high-aﬃnity cell surface receptors speciﬁc for each cytokine
or cytokine group, which, when bound, leads to changes
in the pattern of cellular RNA and protein synthesis [16].
Theyfacilitatecommunicationbetweencells,especiallythose
of the haemopoietic and neuroendocrine systems. The
evolution of the genes that encode the current spectrum of
cytokines and receptor complexes involved multiple duplica-
tions from a smaller set of genes followed by the divergence
of sequence and product function [17]. Recognition between
distant cells is a phenomenon that is almost as old as
metazoa itself dating back at least one billion years. A
clear example of cell-to-cell recognition can be found in
protozoa during sexual reproduction when recognition and
signalingoccursbetweencellshavingacellsurface-associated
set of “permissive” molecules which allow conjugation and
exchange of genetic material between individual cells [18].
A marine ciliate protozoa (Euplotes raikovi)p r o d u c e sa n d
releases speciﬁc pheromones into seawater which bind to
receptors present on cells that are at the same point in
the cell cycle and trigger molecular pathways which lead
to a reciprocal search for permissive partners and to sexual
reproduction [19, 20]. One of these pheromones was capable
of binding to the α and β subunits of the IL-2 receptor
on mammalian cells, and interleukin-2 (IL-2) was able to
bind to its putative receptors on the ciliate protozoa cell
surface. The implications of distant kinship suggested by
these ﬁndings between IL-2 and pheromone families are4 Autoimmune Diseases
supported by similarities in the structures of these molecules
which suggest a conservation of this cell signaling system
during evolution [21]. A similar cross reaction that conﬁrms
an ancestral relationship between ligands and receptors is
seen in a cytokine-like factor with proinﬂamatory functions
found in the blood of the starﬁsh Asterias forbesi. This
factor stimulates monocyte chemotaxis and macrophage
activation in mammals [22, 23]. The mussel Mytilus edulis
has been the subject of studies to determine whether the
relationships between the immune and neuroendocrine
systems, observed in vertebrates, may also be present in
invertebrates. The eﬀects of rIL-1 and tumor necrosis factor
α (TNF-α) were studied in Mytilus hemocytes previously
shown to produce and react to opioid peptides. These cells
responded to these cytokines both in vitro and in vivo,i na
manner similar to that of human granulocytes. In addition,
the presence of immunoreactive IL-1 and TNF in Mytilus
hemolymph was demonstrated using polyclonal antibodies
against mammalian cytokines [24].
2.2.1. IL-1. The family of the IL-1 is made up of IL-
1α,I L - 1 β, IL-18, which are proinﬂamatory cytokines, and
the IL-1 receptor antagonist (IL-1ra) with pivotal roles in
the regulation of acute inﬂammation. The inactive IL-1
precursors of mammals must be cleaved intracellularly by
the IL-1 converting enzyme (ICE) to release the biologically
active form [25]. The nonmammalian vertebrate IL-1 lacks
the sequence coding for the ICE cleavage site and requires
another mechanism to active the cytokine [26]. IL-1 activity
occurs as a consequence of binding to its receptor complex
(IL-1R) on the cell surface of target cells. The binding of
IL-1 to its receptor triggers complex intracellular pathways
that result in the activation of new genes or modiﬁcation
of proteins. As already mentioned, the intracellular domain
of the IL-1 receptor is a “TIR domain” and is similar to
the intracellular domain of TLR. TIR domains participate in
host defense and inﬂammation and are present in mammals,
insects,andplants[27].AnIL-1-likecytokine,whichinduces
increased vascular permeability in rabbit skin, has been
reported in ascidians. This eﬀect was neutralized by a
polyclonal antihuman IL-1 antiserum [28]. In humans, a
diﬀerentformofpolymorphisms,SNPs,areimplicatedinthe
severity of a number of autoimmune diseases such as RA in
which an adequate balance between IL-1 and IL-1ra is also
required [29].
2.2.2. TNF-α. TNFα, mainly produced by monocytes/ma-
crophages, regulates inﬂammation and cellular immune
responses [30]. One of its functions is the modulation of
the expression of IL-1, IL-6, and chemokines [31]. TNF-α
requires a converting enzyme (a metalloproteinase), which
generates a 17kDa soluble mature peptide. The active form
of TNF-α is a homotrimer that binds to two distinct
receptorsonthecellsurface,TNFR1andTNFR2,whichelicit
diﬀerent cellular responses including cellular diﬀerentiation,
proliferation, and apoptosis. Several proteins that interact
with the cytoplasmic domains of these receptors have been
identiﬁedandincludethesignalingcascadesthatleadtoacti-
vation of NF-kB, c-Jun N-terminal kinase, and the apoptotic
pathway. Teleost ﬁsh has TNF-α and TNF-α receptors and
the human recombinant TNF-α produces biological eﬀects
such as macrophage respiratory burst activity, neutrophil
migration, and lymphocyte proliferation [32]. A similar
cross-reaction observed with IL-1 conﬁrms an ancestral
relationship with other species. Inﬂiximab, a chimeric
antibody in which the Fab portion has a mouse origin
eﬀectively blocks the human TNFα molecule and provides
a clinical beneﬁt for patients with active RA [33]. TNF-α and
their receptors have been implicated in the pathogenesis of
diverse autoimmune diseases with special interest in their
polymorphisms [34]. A regulatory mechanism for reducing
the inﬂammatory response in infections such as tuberculosis
(TB) is presumably the development of polymorphism by
natural selection. The −308 and −238 single nucleotide
polymorphisms (SNP) of TNF-α may inﬂuence the presence
of autoimmune diseases and TB. In fact, TNF −308G was
both associated with TB and protective for autoimmunity,
TNF −238A allele was protective for autoimmunity but
represented a susceptibility factor for TB, and the haplotype
−308A −238G was a protective factor against TB while, at
the same time, it carried susceptibility for RA, SLE, and
Sj¨ ogren’s syndrome (SS) [35]. These results support the
hypothesis that autoimmune diseases are a consequence of
natural selection for enhanced TB resistance. Likewise, it
is important to know that evolutionary mechanisms have
been developed for the production of TNF-α regulatory
mechanisms, and their disruption can lead to an increase in
actionandbeassociatedwithautoimmunity.Tristetraproline
(TTP) is one of them. The TTP family of CCCH tandem
zinc-ﬁnger proteins consists of three known members in
mammals with a fourth member recently identiﬁed in frogs
andﬁsh[36].TTPisnowknowntobindtotheso-calledclass
II AU-rich elements within the mRNAs that encode TNF-α
and the granulocyte/macrophage colony-stimulating factor
(GM-CSF). In both cases, this binding results in destabiliza-
tion of the mRNA and decreased secretion of the protein.
Recent evidence suggests that TTP can accomplish this
accelerated mRNA degradation by ﬁrst promoting removal
of the polyadenylated tail from the mRNA (deadenylation)
[37]. A TTP deﬁcient mouse develops a deep inﬂammatory
syndrome with erosive arthritis, autoimmunity, and myeloid
hyperplasia[38].InpatientswithRA,alowTTP/TNF-αgene
expression ratio could indicate failure to produce adequate
amounts of TTP in response to increased TNF-α production
[39].
2.3. Complement System. Serine proteinases appeared early
in evolution. They have even been found in bacteria [40]
and evolved to supply several physiological needs in the
immune system and others. A serine proteinase cascade
which shows similarities to the blood clotting system and
the complement system of vertebrates is involved. There is
even a functional link between immunity and haemostasis,
so coagulation factors activate immunological processes and
various components of the complement also activate coagu-
lation factors [41, 42]. Substrates of these protease cascades
show evolutionary relationships. The complement system
has more than 30 components. About one-fourth of themAutoimmune Diseases 5
are serine proteases that are important for the activation
or regulation of the system. The three branches of the
complement in mammals are classical, lectin, and alternative
pathways that converge in C3 protein and continue until
the terminal phase with the C9 assembled to form the
membrane attack complex (MAC). The complement system
plays important roles not only in defense but also in normal
tissue regeneration and development. The complement par-
ticipates in the removal of immune complexes, aberrant and
apoptotic cells, and cell debris and has important functions
which, if they fail, are implicated in autoimmunity.
2.3.1. Initiating Enzymes. The classical pathway is triggered
by antigen-antibody complexes and the proteases involved
are C1r, C1s and C2. The lectin pathway is triggered
by mannan-binding lectine and the proteases involved
are mannan-binding-protein-associated serine proteases
(MASP)-1, MASP-2, and MASP-3. The alternative pathway
is triggered by pathogen and the proteases involved are
factor D and factor B. The classical pathway is the newest
phylogenetically and participates in the link between innate
and adaptive immune systems. The deﬁciencies of C1q, C1r,
C4, C2 are associated with SLE development by the failure
to remove circulating immune complexes which may be
deposited in blood vessel walls and tissues [43].
2.3.2. C3. The central component of the complement system
is the C3 protein when the three pathways converge. It
has been identiﬁed in jawless vertebrate and derives from a
common ancestor, α-2-macroglobulin. This has been found
in vertebrates, arthropods, and mollusks thus suggesting an
early evolutionary origin and showing its importance as
a defense molecule [44]. It contains an unstable internal
thioether bond that, in nonactivated form, is buried in a
hydrophobic pocket. When the protein is active, there is a
cleavage of the thioether bond which allows the formation of
a stable covalent bond with an adjacent substrate or water.
C3 can be cleaved spontaneously in the alternative pathway
or by other enzymes in the classical and lectin pathways.
These processes must be regulated by proteases that promote
proteolytic degradation of C3 (factor I and factor H in an
alternative pathway), and their deﬁciency is associated with
immune complex-mediated glomerulonephritis.
2.3.3. MAC. In the terminal complement component or
lytic pathway, the C5, C6, C7, C8, and C9 proteins are
present. The later conﬁgures the MAC which forms pores
on the plasma membrane of the target cell, disturbs the
membrane potential, and ﬁnally leads to cell lysis by a
mechanism similar to perforin, which is the lytic protein of
naturalkillercellsandcytotoxiclymphocytes[45].Molecules
homologous to mammalian C5 have been described in
several species of teleost ﬁsh [46]. All these molecules share
common structural motifs, that is, thrombospondin (TS),
low-density lipoprotein receptor (LDL-R), and epidermal
growth factor precursor (EGFP) domains. The cloning of
a C6-like gene from the most primitive of present-day
chordates,theamphioxusBranchiostoma,suggestsanancient
origin of the C6/C7/C8/C9/perforin gene family. It seems
reasonable for the duplication of an ancestral gene to have
proceededthroughthesepathways.Onepathwaypresumably
led to the simple form of perforin while the second produced
the ancestor of C6-C7 with its complex modular structure.
Further duplication and loss of modules may have led to
the creation of C8 and C9 molecules. The MAC present in
teleost ﬁsh closely resembles the mammalian complex. CD59
is a regulatory factor of the terminal complement system. It
blocks C9 binding and prevents the formation of MAC. Its
deﬁciency is associated with hemolytic anemia.
2.4. Receptors for the Fc Region of IgG. (FcgR) provides a type
of link between the humoral and cellular immune system.
Inherited FcgR polymorphisms inﬂuence human phagocyte
function. Single-aminoacid/SNP substitutions within the
extracellulardomainsofFCgRaltertheabilityofthereceptor
to bind IgG and have been associated with the develop-
ment of autoimmune and infectious diseases [47]. FCgRII
(CD32) has two isoforms, FCgRIa and FCgRIIb, which
are expressed on mononuclear phagocytes, neutrophils, and
platelets. FCgRIIa has 2 codominantly expressed alleles,
H131 and R131, which diﬀer at aminoacid position 131
in the extracellular domain (histidine or arginine, resp.)
and diﬀer substantially in their ability to bind human
IgG2 [48, 49]. H131 is the high-binding allele, R131 the
low-binding allele and heterozygotes have an intermediate
function [50]. FcgRIIa-H131 is essential for handling IgG2
immune complexes. These immune complexes are removed
from circulation, primarily in the liver and spleen, by
the mononuclear phagocyte system. Impaired removal of
immune complexes is present in SLE which leads to an
increase in the probability of tissue deposition of immune
complexes, release of inﬂammatory mediators, inﬂux of
inﬂammatory cells, and damage to target-organs such as in
the case of nephritis [51, 52]. FCgRIIb is the only FCgR
inhibitor and regulates signalling which is crucial for the
maintenance of B-cell tolerance and for the ﬁne tuning
of inﬂammatory and immune responses [53]. FCgRIIb-
deﬁcient mice are prone to inducible autoimmunity and,
in some circumstances, develop spontaneous SLE [54]. In
contrast, they are protected from both bacterial infection
[55]a n dm a l a r i a[ 56]. In humans, several SNPs that modify
the expressions or function of FCgRIIb have been described.
A promoter polymorphism that may inﬂuence expression
and be associated with SLE has been described [57]. An
S N Pi ne x o n5o fFCGR2B results in an isoleucine to
threonine substitution within the transmembrane domain
(1232T, rs1050501) which leads to the loss of the inhibitory
function associated with the exclusion of FCgRIIb from lipid
raft [58]. Homozygosis for this SNP is strongly associated
with SLE [59, 60] and is found in 1% of Europeans, 5–7%
of South-East Asian and Kenyans and in more than 10%
of African-Americans. The high prevalence of this SNP in
African and Asian populations may be due in part to the
observation that it not only predisposes to SLE, but also
protects children from malaria [61]. This is another example
of how the eﬀects of evolution based on natural selection can
inﬂuence the genesis of autoimmune phenomena. FcγRIII6 Autoimmune Diseases
(CD16) has two isoforms, FcγRIIIa and FcγRIIIb. FcγRIIIb
has two codominantly expressed alleles: NA1 and NA2 with
changes in the aminoacid sequences that may also alter
the aﬃnity to immune complexes. The ﬁrst has a low
binding to the immune complex and is more associated with
autoimmune processes such as antineutrophil cytoplasmic
antibody (ANCA)-positive systemic vasculitis [62]. In SS,
thereisasimilarcorrelationwiththepresenceofFCgRII[63]
and FCgRIII [64]p o l y m o r p h i s m s .
Therefore, we postulate that primitive animals with an
innate immune system may have been attacked by their own
systematdiﬀerenttimesduringevolutionand,consequently,
developed regulatory mechanisms such as RNAi, TTP, IL-
1ra, regulator complement cascade proteins, and FCgRIIb
presented above. Another regulatory mechanism which is
implicated in autoimmune phenomena when it fails is the
one associated with the functions of suppressor T cells
[65].
2.5. Class III Major Histocompatibility Complex (Class III
MHC). This loci contains several genes that encode secreted
proteins that play innate immune functions: components of
the complement system (such as C2, C4 and factor B) and
inﬂammation-related molecules (cytokines such as TNF-
α, LTA, LTB) or HSP. Class-III has a completely diﬀerent
function classes-I and II (described below in the text),
but is between the other two in the short arm of human
chromosome 6.
3. Inﬂuence of the Second Form of Evolutionary
Memory in Autoimmune Phenomena
Adaptive immunity is a form of second evolutionary
memory and stores molecular information in microbes in
o r d e rt oh a v eaq u i c k e ra n dm o r ee ﬀective defense against
them in future exposures through cytokines and speciﬁc
antibodies. The most important mechanism that nature
has used to obtain and retain this type of information
has been the immunoglobulin superfamily gene system
whichprovidesinformationtocreatemultiplereceptors.The
adaptive immune system, as deﬁned by rearranging antigen
receptor genes in the immunoglobulin superfamily and by
the major histocompatibility complex, has only been found
in the jawed vertebrates (gnathostomes). The mechanism of
recombination-activating gene (RAG)-mediated rearrange-
ment exists in all jawed vertebrates, but the organization
and structure of immunoglobulin (Ig) genes, as they diﬀer
among ﬁsh and ﬁsh species, reveal their capability for
rapid evolution. Recombination among these loci created
hybrid genes, the strangest of which encodes variable (V)
regions that function as part of secreted molecules and,
as the result of an ancient translocation, are also grafted
onto the T-cell receptor [66]. Other groups of proteins
that belong to the immunoglobulin superfamily with a
common ancestral origin are FcγR and immunoglobulin-
like receptor (KIR) which have an important function in the
infection inﬂammatory response and the alteration of which
is associated with autoimmune-type responses.
3.1. Autoantibodies, Autoantigens. The antibodies directed
against their own structures (autoantibodies) have a primary
role in autoimmunity being pathogenic in diseases caused
by an attack on cell or tissue antigens (autoantigens),
or in immune complex-mediated diseases. Several factors
are implicated in this deviation from the primary role of
the antibodies humeral immunity: (1) the formation of a
repertoire of B cells that attack their own structures as they
do not do adequate receptor editing or negative selection,
(2) the recognition of autoantigens as foreign because they
are similar to the structures of microorganisms (molecular
mimicry), or (3) the possibility of not adequately removing
immune complexes. The autoantigens may be from diﬀerent
sources.
3.1.1. Protein Structures That Are Present in the Organs and
Which Are “Visible” to the Immune System. These molecules
may have structural or functional roles and are usually
common among mammals. Humans and mice share most
of their genome. The passive immunization of mice with
antibodies from human patients with autoimmune diseases
can reproduce components of the diseases.
3.1.2. Proteins That Are Hidden in the Tissues and by Factors
Such as Trauma Begin to Be Recognized by the Immune System
as Foreign. The system starts processes to eliminate them
withinnate mechanisms initially and afterthatwithacquired
immunity mechanisms. An example of this condition is the
sympathetic ophthalmia (SO) where breaching of systemic
ocular barriers compromises the relative immune privilege
of the eye and causes sensitization to previously sequestered
uveoretinal antigens [67]. A similar mechanism is observed
in relapsing polychondritis which begins with cartilage
trauma and is triggered by an immune response to other
cartilaginous or noncartilaginous tissues [68].
3.1.3. Even Though There Are Proteins That Are Not Present
in the Human Structure, the Genetic Information Is Present.
These genes are ancestrally repressed and hidden. As a result
of diﬀerent causes, they start the protein synthesis and this
“foreign” protein is attacked by the immune system. An
example is the endogenous retrovirus (ERV) which belongs
to the large family of retrotransposable elements of human
genoma [69]. ERV may have originated from an exogenous
retrovirus that integrated ancestrally into the genoma and
became trapped owing to mutations of essential genes and is
transmitted genetically in the classical Mendelian form [70].
ERV is strand RNA viruses with a mode of replication in
which the RNA genome is transcribed into DNA by reverse
transcriptase. ERV may be activated by radiation, bacteria,
chemicals, or recombination with an exogenous retrovirus
[71, 72] and starts the “autoantigen” protein synthesis that
is the source for autoimmune processes implicated in the
pathogenesis of SLE [73]. Another mechanism is the biologi-
caleﬀectofaviralproduct.Forexample,certaincomponents
derivedfromendogenousretrovirusespl5Epresentinseveral
species, including murine, feline, and human, induce the
immune abnormalities observed in SLE lymphocytes [74].Autoimmune Diseases 7
3.1.4. Ancestral Proteins Become Visible to the Immune System
Through Diverse Stimuli Because They Are Trying to Perform
Functions That Are no Longer Present in Our Species. This
concept is part of an “atavist” hypothesis of pemphigus
vulgaris based on the mechanism of shedding in reptiles
[75, 76].
3.2. Classes I and II MHC. In vertebrates, allorecognition
depends on proteins encoded by MHC genes. An MHC-
like region is certainly very ancient and is believed to be
presentinthecommonancestorofproto-anddeuterostomes
[77]. The function of MHC is to present antigens to T cell
receptors.Ithasbeenproposed thattheMHCregionaroseas
a result of chromosomal duplications. In higher vertebrates,
MHC is represented by two distinct classes, MHC I and
MHC II. In the intracellular processes, the participation of
chaperons and transporter molecules is necessary. The most
likely hypothesis is that the ancestral MHC molecule had
a class II-like structure which later gave rise to a class I
molecule [78, 79].
3.2.1. Class I MHC. This is widely distributed and is ex-
pressed on most nucleated cells. As a general rule, antigens
generated within the cell (endogens) are processed in the
cytosolic pathway, transported with class I MHC molecules
to the plasma membrane of most nucleated cells and
presented to T-cells. Class I MHC requires proteasomes
for antigen generation. These structures are phylogenetically
ancient as they are found both in bacteria and eukaryotes.
Peptides generated by the proteasome in Drosophila and
yeast,whichlackMHC,arereroutedtowardsanewbiochem-
ical pathway viathe peptide transporters. Agnathans lack the
ability to produce immunoproteasomes [80].
3.2.2. Class II MHC. Antigens taken up by phagocyto-
sis (exogenous) are processed in the endocytic pathway,
transported with class II MHC molecules, and presented
in the membrane of macrophages, dendritic cells, and B
cells. They are assembled within the rough endoplasmic
reticulum where they associate with a glycoprotein called
invariantchain(Ii,CD74)whichpreventsprematurebinding
of any endogenously derived peptides. Afterwards, CD74
is digested by cathepsins S and L in order to free the
binding fragment (CLIP). The removal of CLIP and peptide
loading requires HLA-DM, an endosome-resident accessory
molecule. In mammalian B cells, peptide loading is further
modulated by another molecule, HLA-DO. The invariant
chain glycoprotein, CD74, is found only in the gnathostome
vertebrates. Several cathepsins seem to have been associated
with class II MHC for peptide presentation several times
duringevolutionatthelevelofexogenouspeptideprocessing
and processing of CD74 [81]. Class II MHC polymorphisms
have been studied and their presence is a risk factor for var-
ious autoimmune diseases, for example, HLA DRB1∗04 in
RA,HLADRB1∗0301inSLEoHLADR1∗0301-DQB1∗0201
in SS [82]. Sometimes the risk is caused by the combination
of polymorphisms (haplotypes) such as the 8.1 ancestral
haplotype [83]. The presence of these molecules is associated
with the common genesis of several autoimmune diseases
(autoimmune tautology) [84]. In other mammals, similar
associations have been shown [85].
4. Inﬂuence of the Third Form of Evolutionary
Memory in the Autoimmune Phenomena
Memory related to neuronal function in relation to autoim-
mune phenomena is a crucial factor for storing diverse
experiences during life.
4.1. Neuroimmunoendocrine Network. An emotion such as
stress triggers endocrine responses which, in turn, aﬀect the
immune system and cause its activation and inappropriate
response in the setting of autoimmune and infectious
diseases. Many retrospective studies found that a high
number of patients reported uncommon emotional stress
before disease onset. Other studies suggest that stress is
not only a participating factor but may also be a cause of
disease exacerbations. Unfortunately, it is a vicious cycle
because stress not only causes disease but the disease itself
causes considerable stress in patients [86]. Neuroendocrine
hormones triggered during stress may lead to immune
dysregulation or altered or ampliﬁed cytokine production
thus resulting in autoimmune diseases. Various types of
transmitter substances in the neuroendocrine-immune net-
work include epinephrine, norepinephrine, acetylcholine,
substance P, vasoactive intestinal peptide, glucagon, insulin,
cytokines,andgrowthfactors.Thestressresponseandinduc-
tion of a disregulation in the cytokine balance can trigger
the hypothalamic-pituitary-adrenal axis and sympathetic
nervous system [87].
4.2. Neuron-Glial Relationship. Another type of information
stored in the brain is related to the experience of pain.
Somatic pain induces an immediate response that generates
the reﬂex which moves the injured body part and prevents
an increase in the damage. A second form of pain is the
subacute or chronic somatic pain that is caused by the rest
of the aﬀected area during the repair process. Another form
of pain is the neuropathic pain which is due to the persistent
response that is generated after an injury to peripheral nerve
structures[88].Inthisconditionthemicroglia,whicharethe
resident macrophages of the brain and spinal cord, plays an
important role. It seems that the nerve injury activates the
receptor TLR4 which is only expressed in the central nervous
system on microglia. Genetically altered mice lacking TLR4
showed markedly reduced microglial activation after nerve
injury as well as reduced sensitivity to pain [89]. Another
candidate trigger for microglial activation after nerve injury
is fractalkine, a CX3C chemokine, expressed on the surface
of neurons [90]. But, how does microglia excite sensory neu-
rons?Manyresearchershavesuggestedthatproinﬂammatory
cytokines secreted by activated microglia increase neural
excitability and sensitivity to pain when injected into the
spinal cords of rats. It is possible that many brain functions
allocated exclusively to neurons are dependent on a neuron-
microglia interaction. Ontogenetically both microglia and8 Autoimmune Diseases
otherglialcellsareimportantintheprocessofmigrationand
location of neurons in the central nervous system and are
also closely related to their control electrolyte and nutrient
supply [91]. Not only glial cells but also neurons respond
to the presence of several cytokines [92]. The concept
of integrated neuroendocrine-immune regulation has now
been widely accepted although the physiological impact
on normal development and homeostasis or conditions of
mental stress or physical disease are still poorly understood
[93]. The actions of cytokines via their receptors may also
have physiopathological implications in other conditions
such as multiple sclerosis, Alzheimer’s disease, and AIDS
dementia syndrome [94, 95].
4.3. Role of IL-1 and IL-1Rs. A well-known example is the
role of IL-1 in the stress-axis, the hypothalamis-pituitary-
adrenal(HPA)axisinmammals[96].Thisaxisisactivatedby
inﬂammatory cytokines like IL-1 through the release of the
corticotrophin releasing hormone (CRH) and proopiome-
lanocortin (POMC)-derived adrenocorticotropic hormone
(ACTH) from the hypothalamus and anterior pituitary
gland, respectively [97, 98]. Upon the release of ACTH, cor-
ticosteroid production, and release from the adrenal cortex
will be stimulated which, in turn, causes redistribution of
leukocytes, inhibition of antibody production and release of
inﬂammatory cytokines. IL-1R family members are encoded
on the X chromosome and they are present in multiple
teleost orthologues as well as in chickens. In mammals,
they are abundantly expressed in the hippocampal memory
system of the brain and therefore might contribute to brain
development or function [99]. Interestingly, mutations in
this loci are responsible for a hereditary form of mental
retardation [100, 101].
5. Inﬂuence of the Fourth Form of Evolutionary
Memory in the Autoimmune Phenomena.
The fourth form of mankind’s evolutionary memory is
culture, and with this, there are many conditions that are
related to the genesis of autoimmune phenomena. Humans
who have changed to an urban environment have undergone
changes in their exterior stimuli which their biological
structure cannot be adequately adapted to given the limited
period for that adaptation.
5.1. Changes in the Diet. Dietary modiﬁcations for humans
that led to protein-calorie malnutrition or otherwise to
weight excess have been assessed and taken into account
when seeking nutritional factors associated with develop-
ment of autoimmunity [102, 103]. The lack of exposure
to various antigens in early childhood, including the newly
born and those growing up in an “aseptic,” environment
results in a very low exposure to antigens required for
the development of cell-mediated immunity (leading to
better and safer protection) and, at later stages, requires an
antibody-mediated protection which can lead to allergy and
autoimmunity phenomena [104].
5.2. Changes in Exposure to Ultraviolet (UV) Radiation. It
is well known that industrialization decreases exposure to
sunlightwiththeconsequentdevelopmentofvitaminDdeﬁ-
ciency, now a well-studied factor related to autoimmunity
[105].Attheotherextreme,theoverexposuretosunlightdue
to working conditions or the cultural practice of changing
the color of the skin (tanning) increases UV radiation. This
is related to the development or exacerbation of cutaneous
lupus and SLE by diﬀerent mechanisms [106, 107].
5.3. Eﬀects Related to Jobs and Habits. Some jobs are related
to risks of SLE. For example, school teachers are exposed
to many viruses that can be the basis for an abnormal
immune response in a genetically predisposed individual
[108]. Various habits such as smoking [109]o re x p o s u r et o
smog-relatedparticles[110]arealsoassociatedwithasimilar
outcome.
5.4. Eﬀects of Exposure to Drugs. With the evolution of
human culture, pharmacology also developed and diverse
drugs could induce autoimmune phenomena through var-
ious factors including epigenetic ones (Example: pro-
cainamide, hydralazine, Chlorpromazine, isoniazid, pheny-
toin, and penicillamine) [111]. Women have a greater pre-
disposition to developing autoimmunity in part as a result of
the eﬀect of estrogen, which, when used for therapeutic or
contraceptive reasons, increases the risk [112].
5.5. Eﬀects of Migrations and Social Aspects. It has been
postulated that older factors such as migration and exposure
for long periods of time to diﬀerent forms of environment
were determining factors for the development of diﬀerent
human races which have diﬀerent risks for the development
of autoimmune diseases [113–116]. More recently there
has been a genetic mixing of races due to migration and
risk conditions for developing diseases have changed for
each race. Race can also be modiﬁed without requiring
migration; for instance, by religious or political inﬂuences
that encourage the choice of partner for reproduction in
order to ensure a race with certain characteristics which are
more related to beauty and purity [117]. Human society
has the same dynamic processes as nature, which has a
tendency to maintain a status of “entropy” within constant
“chaos” in physicochemical terms, or constant “changes” in
socioanthropological terms [118].
6. Conclusions
One way to understand autoimmunity is through knowledge
of the biological signiﬁcance of evolution. Since a specialized
system for defense against microorganisms was set up,
living things have theoretically been vulnerable to devel-
oping autoimmune phenomena. The existence of diﬀerent
regulatory mechanisms can only be explained as strategies
that were developed to avoid these phenomena of self-
destruction. The human species have a cumulative evolution
of the most complex mechanisms of innate and acquired
immunity which makes it very vulnerable to autoimmunityAutoimmune Diseases 9
especially when the regulatory mechanisms fail. Other risk
factors are not inherited and are the product of the evolution
of the brain and culture in the human species.
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